361 Capital’s Acorda Therapeutics ACOR Stock Holding History

361 Capital’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-733	Closed	-$1.17M	–	406
2019 Q1	$1.17M	Buy	+733	New	+$1.32M	0.2%	198

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

361 Capital's ACOR Position: Q2 2019 in Review

361 Capital sold out of Acorda Therapeutics (ACOR) in Q2 2019, closing a stake of 733 shares — an estimated $1.17M sold.

361 Capital first reported a position in ACOR in Q1 2019 and held it in 1 quarter. The position peaked at $1.17M in Q1 2019. 163 funds tracked by Wall St. Rank hold ACOR as of Q2 2019.

361 Capital reported no remaining Acorda Therapeutics position as of Q2 2019 after selling out during the quarter.
361 Capital sold 733 Acorda Therapeutics shares in Q2 2019, an estimated $1.17M.
361 Capital first reported a position in Acorda Therapeutics in Q1 2019 and held it in 1 quarter.
361 Capital's Acorda Therapeutics position peaked at $1.17M in Q1 2019.
163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2019.

Based on 361 Capital's 13F filing for Q2 2019, filed 7 Aug 2019.